N/A N=146 Swallowing Function Before and After Surgery for Thyroid Goiter
Hypothyroidism
Primary: Swallowing Quality of Life — 84.6; 92.3; 81.2; 87.1 units on a scale — p=0.0007
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=38 Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules
Benign Thyroid Nodule
Primary: Percent Change in Area of Thyroid Nodules — -19.98; -9.31 percentage change — p=0.047
Phase 1 N=12 ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Phase 4 N=30 Preoperative Steroids in Autoimmune Thyroid Disease
Thyroid Diseases
Primary: Thyroid Difficulty Scale Score — 9.8; 9.75 score on a scale
Phase 2 N=19 Radioactive Iodide Therapy for Pediatric Graves' Disease
Graves' Disease
Primary: Dosimetry Studies
Phase 4 N=66 Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors
Hypothyroidism;Postablative
Primary: Thyroid Stimulating Hormone (TSH) — -0.676 mIU/L — p=<0.0001
Phase 4 N=36 Impact of SSKI Pre-Treatment on Blood Loss in Thyroidectomy for Graves Disease
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
N/A N=68 Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism
Congenital Hypothyroidism
Primary: Dose Adjustments — 2.5; 2.4 Number of dose adjustments
Phase 3 N=1,203 Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy
Subclinical Hypothyroidism · Hypothyroxinemia · Pregnancy
Primary: Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or…
Phase 2 N=27 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Head and Neck Cancer
Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants
N/A N=843 Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure
Hypothyroidism
Primary: Number of Pediatric Patients With Detected Hypothyroidism After Iodinated Contrast Exposure in a Routine Clinical Practice Setting — 11 Participants
N/A N=2,320 Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States
Hypothyroidism
Primary: Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice — 15.9 events per 1,000 person years
Phase 2 N=14 Thyroid and Glucose and Energy Metabolism
Thyroid Diseases
Primary: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase — 7.26 mg/kg/min
N/A N=12 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Papillary Carcinoma of Thyroid Gland · Metastatic Medullary Thyroid Cancer · Follicular Thyroid Cancer Lymph Node Metastasis
Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…
N/A N=111 Assess Vitamin D Levels in Those With & Without Thyroid Cancer
Thyroid Cancer
Primary: Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups. — 23; 20; 11 participants…
N/A N=55 Ultrasound Elastography in Imaging Patients With Thyroid Nodules
Malignant Thyroid Gland Neoplasm · Thyroid Gland Nodule
Primary: Stiffness of Thyroid Nodules as Measured by Elastography — 2.7; 3.8; 2.7 meters/second
Phase 2 N=60 Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants
Phase 2 N=7 Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
Insulin Resistance · Diabetes Mellitus · Abnormal Glucose Metabolism
Primary: Total Body Glucose Disposal in the Fasting State — 21.47 μmol/kg LBM (Lean Body Mass)/min
N/A N=90 FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)
Hashimoto Disease
Primary: Fibroblast Growth Factor 21 (FGF-21) — 182.71; 217.36; 198.43 pg/mL
Phase 2 N=63 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
Phase 2 N=34 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Thyroid Cancer · Differentiated Thyroid Carcinoma
Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…
Phase 2 N=27 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
N/A N=126 The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer
Thyroid Cancer · Thyroid Nodule · Benign Thyroid Nodule
Primary: Treatment Choice — 54; 51; 6; 7 Participants — p=0.720
Phase 2 N=7 Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
Graves' Ophthalmopathy
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Phase 2 N=52 Nivolumab Plus Ipilimumab in Thyroid Cancer
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Phase 2 N=13 Energy Metabolism in Thyroidectomized Patients
Thyroid Goiter · Hypothyroidism · Thyroid Cancer
Primary: Short Term Change in Weight — 1.7; -0.76 Kilogram
Phase 3 N=417 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Thyroid Neoplasms
Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001
N/A N=107 AIM2: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid
Thyroid Nodules · Thyroid Cancer
Primary: Proportion of Eligible Patients for Feasibility — 213; 318 Participants